BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18241246)

  • 1. Metastatic non-clear cell renal cell carcinoma: current therapeutic options.
    Schrader AJ; Olbert PJ; Hegele A; Varga Z; Hofmann R
    BJU Int; 2008 Jun; 101(11):1343-5. PubMed ID: 18241246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options.
    Bellmunt J; Eisen T; Szczylik C; Mulders P; Porta C
    BJU Int; 2011 Apr; 107(8):1190-9. PubMed ID: 21078050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of metastatic renal cell carcinoma.
    Reeves DJ; Liu CY
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy of renal cell cancer.
    Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
    Curr Opin Investig Drugs; 2008 Jun; 9(6):570-5. PubMed ID: 18516756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EORTC-GU group expert opinion on metastatic renal cell cancer.
    de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
    Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes and prognosis in advanced renal cell carcinoma.
    Galsky MD; Vogelzang NJ
    Expert Rev Anticancer Ther; 2007 Jun; 7(6):839-45. PubMed ID: 17555394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapeutics for metastatic renal cell carcinoma.
    Hutson TE; Figlin RA
    Cancer; 2009 May; 115(10 Suppl):2361-7. PubMed ID: 19402059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma.
    Ismail S; Meskawi M; Hansen J; Bianchi M; Tian Z; Latour M; Graefen M; Montorsi F; Trinh QD; Perrotte P; Karakiewicz PI; Sun M
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):49-57. PubMed ID: 24411587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temsirolimus in renal cell carcinoma.
    Otto T; Eimer C; Gerullis H
    Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma.
    Rini BI; Flaherty K
    Urol Oncol; 2008; 26(5):543-9. PubMed ID: 18774471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies.
    Tan TH; Pranavan G; Haxhimolla HZ; Yip D
    Asia Pac J Clin Oncol; 2010 Mar; 6(1):5-18. PubMed ID: 20398033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New treatment approaches in renal cell carcinoma.
    Facchini G; Perri F; Caraglia M; Pisano C; Striano S; Marra L; Fiore F; Aprea P; Pignata S; Iaffaioli RV
    Anticancer Drugs; 2009 Nov; 20(10):893-900. PubMed ID: 19752718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the medical treatment of metastatic renal cell carcinoma.
    Ravaud A; Wallerand H; Culine S; Bernhard JC; Fergelot P; Bensalah K; Patard JJ
    Eur Urol; 2008 Aug; 54(2):315-25. PubMed ID: 18485581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on novel agents in renal cell carcinoma.
    Tamaskar I; Pili R
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1817-27. PubMed ID: 19954293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapeutic developments in renal cell cancer.
    Prenen H; Gil T; Awada A
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
    Procopio G; Verzoni E; Gevorgyan A; Mancin M; Pusceddu S; Catena L; Platania M; Guadalupi V; Martinetti A; Bajetta E
    Oncology; 2007; 73(3-4):204-9. PubMed ID: 18418013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney.
    Ansari J; Fatima A; Chaudhri S; Bhatt RI; Wallace M; James ND
    Onkologie; 2009 Feb; 32(1-2):44-6. PubMed ID: 19209019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
    Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
    J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapies and the treatment of non-clear cell renal cell carcinoma.
    Bellmunt J; Dutcher J
    Ann Oncol; 2013 Jul; 24(7):1730-1740. PubMed ID: 23625974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine therapy in patients with renal cell carcinoma.
    Van Poppel H; Joniau S; Van Gool SW
    Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.